TG Therapeutics Investigational Trial Site

Lexington, Kentucky 40513

1 studies enrolling now · 3 studies all time

What they study most

Multiple Sclerosis, Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis

Studies at this site

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — Recruiting now
• An Extension of the TG1101-RMS201 Trial — Completed
• Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis — Completed